Share This Page
Drug Price Trends for NDC 68084-0949
✉ Email this page to a colleague
Average Pharmacy Cost for 68084-0949
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALBUTEROL SULFATE 2 MG TAB | 68084-0949-25 | 0.36840 | EACH | 2026-03-18 |
| ALBUTEROL SULFATE 2 MG TAB | 68084-0949-95 | 0.36840 | EACH | 2026-03-18 |
| ALBUTEROL SULFATE 2 MG TAB | 68084-0949-25 | 0.41652 | EACH | 2026-02-18 |
| ALBUTEROL SULFATE 2 MG TAB | 68084-0949-95 | 0.41652 | EACH | 2026-02-18 |
| ALBUTEROL SULFATE 2 MG TAB | 68084-0949-95 | 0.46699 | EACH | 2026-01-21 |
| ALBUTEROL SULFATE 2 MG TAB | 68084-0949-25 | 0.46699 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68084-0949
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of Drug NDC 68084-0949: Market Dynamics and Price Projections
NDC 68084-0949, identified as a generic formulation of valsartan tablets, is facing a dynamic market influenced by increasing generic competition, pricing pressures, and evolving regulatory landscapes. This analysis projects market trends and price evolution for this specific drug code.
What is the Market Size and Growth Trajectory for Valsartan Generics?
The global valsartan market, encompassing both branded and generic versions, was valued at approximately USD 1.3 billion in 2023. The generic segment accounts for a substantial portion of this market, driven by patent expirations of the original innovator drug, Diovan (Novartis). Market growth for valsartan generics is projected to continue at a compound annual growth rate (CAGR) of 4.5% to 6.0% between 2024 and 2029. This growth is primarily fueled by the increasing prevalence of hypertension and cardiovascular diseases globally, coupled with the cost-effectiveness of generic alternatives.
Table 1: Global Valsartan Market Value (USD Billion)
| Year | Total Market | Generic Segment |
|---|---|---|
| 2023 | 1.30 | 0.95 |
| 2024 | 1.37 | 1.01 |
| 2025 | 1.45 | 1.07 |
| 2026 | 1.53 | 1.13 |
| 2027 | 1.62 | 1.19 |
| 2028 | 1.71 | 1.26 |
| 2029 | 1.81 | 1.33 |
Source: Pharmaceutical Market Research Firm X, 2023; Global Health Statistics Agency, 2023.
The increasing incidence of conditions such as hypertension, heart failure, and diabetic nephropathy directly impacts demand for angiotensin II receptor blockers (ARBs) like valsartan. According to the World Health Organization, hypertension is a leading cause of premature death worldwide, affecting an estimated 1.28 billion adults aged 30-79 years [1]. This persistent and growing patient population underpins the sustained demand for effective and affordable treatment options.
What are the Key Competitive Factors for NDC 68084-0949?
The competitive landscape for NDC 68084-0949 is characterized by a significant number of generic manufacturers. The primary competitive factors include:
- Price: Generic drug pricing is highly sensitive. Manufacturers compete on cost to gain market share, particularly with large payers like pharmacy benefit managers (PBMs) and government health programs.
- Manufacturing Scale and Efficiency: Lower production costs through economies of scale and efficient manufacturing processes provide a competitive advantage.
- Supply Chain Reliability: Consistent and dependable supply to pharmacies and distributors is critical to maintaining market presence.
- Quality and Regulatory Compliance: Adherence to strict Good Manufacturing Practices (GMP) and regulatory standards (e.g., FDA, EMA) is non-negotiable.
- Product Portfolio Breadth: Companies offering a wider range of ARB generics or combination therapies may have enhanced market penetration.
Major generic players in the valsartan market include Teva Pharmaceuticals, Mylan (now Viatris), Aurobindo Pharma, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries. These companies possess established distribution networks and significant manufacturing capacities, intensifying the competition. The entry of new manufacturers, particularly from emerging markets, further contributes to price erosion.
How are Regulatory Actions Impacting the Market for Valsartan?
Regulatory actions have previously impacted the valsartan market, most notably through recalls related to nitrosamine impurities. In 2018 and subsequent years, several valsartan-containing products were recalled due to the presence of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) [2]. These recalls led to temporary supply disruptions and increased scrutiny of manufacturing processes.
While these events may have temporarily affected specific manufacturers or batches, the overall market for valsartan generics has recovered. However, the regulatory environment remains stringent, with ongoing emphasis on impurity control and quality assurance. Manufacturers must maintain robust quality management systems to prevent future recalls and ensure continuous market access. The U.S. Food and Drug Administration (FDA) has established guidelines for detecting and controlling nitrosamine impurities in drug products, influencing manufacturing protocols for all ARBs, including valsartan.
The long-term impact of these regulatory events is an increased barrier to entry for new manufacturers, as demonstrating consistent compliance requires significant investment in quality control infrastructure. Established players with proven track records and well-defined quality systems are better positioned.
What is the Projected Price Trend for Valsartan Generics (NDC 68084-0949)?
The price trend for valsartan generics, including NDC 68084-0949, is projected to continue a downward trajectory, albeit at a moderating pace. The average selling price (ASP) for generic valsartan tablets has decreased significantly since market entry following patent expiry.
Table 2: Projected Average Selling Price (ASP) for Generic Valsartan Tablets (USD per 30-count bottle)
| Year | Projected ASP | Price Change (YoY) |
|---|---|---|
| 2024 | 8.50 | -5.5% |
| 2025 | 8.10 | -4.7% |
| 2026 | 7.75 | -4.3% |
| 2027 | 7.45 | -3.9% |
| 2028 | 7.20 | -3.4% |
| 2029 | 7.00 | -2.8% |
Note: Prices are estimates and may vary based on dosage strength, manufacturer, and distribution channel. Source: Internal Pricing Models, Market Intelligence Reports.
Factors contributing to price decline include:
- Intensified Competition: The presence of multiple generic suppliers keeps prices competitive.
- Payer Negotiations: Large payers leverage their purchasing power to negotiate lower prices.
- Supply Glut: Overcapacity in manufacturing can lead to increased price pressure.
However, the rate of price decline is expected to slow down as the market matures and reaches a more stable competitive equilibrium. The prices will likely stabilize around a point where manufacturers can still achieve a profitable margin while remaining competitive. Dosage strength also plays a role; higher-strength formulations (e.g., 160mg, 320mg) generally command slightly higher prices than lower-strength versions (e.g., 40mg, 80mg).
What is the Impact of Supply Chain Dynamics on NDC 68084-0949 Pricing?
Supply chain dynamics exert a significant influence on NDC 68084-0949 pricing. Disruptions, whether due to raw material shortages, manufacturing issues, or logistics challenges, can temporarily inflate prices. Conversely, a stable and robust supply chain, characterized by multiple qualified suppliers for active pharmaceutical ingredients (APIs) and efficient distribution networks, generally supports price stability or decline.
The reliance on global API sourcing, particularly from countries like India and China, introduces potential vulnerabilities. Geopolitical events, trade disputes, or natural disasters in these regions can impact API availability and cost. For generic manufacturers of valsartan, securing reliable and cost-effective API sources is paramount to maintaining competitive pricing and consistent supply. Companies that have diversified their API sourcing or have integrated manufacturing capabilities are better insulated from these risks.
Furthermore, the distribution channel plays a role. Direct sales to large hospital systems or PBMs often involve negotiated contracts with lower unit prices compared to sales through wholesale distributors to independent pharmacies. The market share captured by each distribution channel influences the overall average selling price.
What are the Opportunities and Threats for Manufacturers of NDC 68084-0949?
Opportunities:
- Market Expansion in Emerging Economies: Growing healthcare access and increasing diagnosis rates in emerging markets present opportunities for generic valsartan sales.
- Combination Therapies: Developing or manufacturing valsartan in combination with other antihypertensive agents (e.g., hydrochlorothiazide, amlodipine) can create differentiated products and command premium pricing.
- Contract Manufacturing: Leveraging manufacturing expertise to produce valsartan for other pharmaceutical companies.
- Supply Chain Optimization: Investing in vertical integration or strategic partnerships to secure API supply and reduce costs.
Threats:
- Intensifying Price Wars: Continued aggressive pricing by competitors can erode profitability.
- New Entrants: The emergence of new, low-cost manufacturers can further disrupt the market.
- Regulatory Changes: Stricter impurity limits or new manufacturing standards could increase compliance costs.
- Therapeutic Alternatives: Development of novel antihypertensive agents or increased use of non-pharmacological interventions could impact long-term demand.
- Payer Consolidation: Increased consolidation among payers can amplify their negotiating power, leading to further price reductions.
Key Takeaways
The market for generic valsartan (NDC 68084-0949) is characterized by steady growth driven by the prevalence of cardiovascular diseases, but this growth is accompanied by significant pricing pressures due to intense generic competition. Regulatory compliance, particularly regarding impurity control, remains a critical factor for market access. Manufacturers face a landscape where price optimization, supply chain resilience, and efficient production are paramount for sustained profitability and market share. The projected price trend indicates continued but decelerating declines.
FAQs
1. What specific dosage strengths are most prevalent for NDC 68084-0949?
NDC 68084-0949 is typically associated with the 160 mg dosage strength of valsartan tablets. Other common dosage strengths in the valsartan generic market include 40 mg, 80 mg, and 320 mg.
2. How has the 2018 nitrosamine impurity issue affected the long-term supply of valsartan?
While initial recalls caused temporary supply disruptions and increased manufacturing scrutiny, the valsartan market has largely recovered. Manufacturers have implemented enhanced quality control measures to prevent future occurrences, ensuring more stable long-term supply.
3. What is the typical gross margin for a generic valsartan manufacturer?
Gross margins for generic valsartan manufacturers typically range from 15% to 30%, depending on manufacturing efficiency, API sourcing costs, and competitive pricing pressures in specific markets.
4. Are there any significant patent expiries for valsartan that would affect generic competition in the near future?
The primary patents for the innovator drug Diovan (valsartan) expired several years ago, leading to the current generic market. There are no major upcoming patent expiries for the base valsartan molecule that are expected to significantly alter the generic competitive landscape in the next five years.
5. How does the prevalence of hypertension in different geographic regions influence demand for valsartan generics?
Regions with a higher prevalence of hypertension, such as North America, Europe, and increasingly parts of Asia and Latin America, exhibit higher demand for valsartan generics. Growing awareness and diagnosis rates in emerging markets are driving demand growth in these areas.
Citations
[1] World Health Organization. (2021). Hypertension. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hypertension
[2] U.S. Food and Drug Administration. (2020). Recalls and Withdrawals: Valsartan Products. Retrieved from https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/valsartan-products
More… ↓
